Related Experiment Video
Updated: Jun 17, 2026

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery
Published on: November 5, 2019
Meningococcal Surveillance Australia: Reporting period 1 October to 31 December 2025
Monica Lahra1, Siobhan Hurley2, Tiffany Hogan2
1NSW Health Pathology, World Health Organization Collaborating Centre for STI and AMR and Neisseria Reference Laboratory, Microbiology, Prince of Wales Hospital, Randwick, NSW 2031, Australia; School of Medical Sciences, Faculty of Medicine, University of New South Wales, Kensington, NSW 2052, Australia. monica.lahra@health.nsw.gov.au.
Abstract:
The reference laboratories of the Australian Meningococcal Surveillance Programme (AMSP) report data on the number of cases of invasive meningococcal disease (IMD) confirmed by laboratory testing using culture and molecular based techniques. Data contained in quarterly reports are restricted to a description of case numbers of IMD by jurisdiction and serogroup, where known and expanded in 2024 to include antimicrobial resistance data for ceftriaxone, penicillin, ciprofloxacin and rifampicin. A full analysis of laboratory confirmations of IMD in each calendar year are contained in the AMSP annual reports.
Related Concept Videos
Bacterial Meningitis I: Introduction
Bacterial Meningitis
Principles of Disease Surveillance
Viral Meningitis
Cryptococcal Meningitis
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...

